Compare RVMD & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVMD | TEVA |
|---|---|---|
| Founded | 2014 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3B | 40.5B |
| IPO Year | 2020 | 1996 |
| Metric | RVMD | TEVA |
|---|---|---|
| Price | $193.42 | $40.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 24 | 13 |
| Target Price | ★ $259.14 | $47.17 |
| AVG Volume (30 Days) | 2.2M | ★ 5.3M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 183.45 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $564.95 | $3.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.05 | $18.83 |
| 52 Week High | $224.31 | $42.02 |
| Indicator | RVMD | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 44.06 | 62.59 |
| Support Level | $188.18 | $30.41 |
| Resistance Level | $194.19 | N/A |
| Average True Range (ATR) | 8.63 | 1.06 |
| MACD | -1.27 | 0.07 |
| Stochastic Oscillator | 41.68 | 69.76 |
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.